机构:[1]The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510006, China广东省中医院
Objective: Tongguan Capsule, a traditional Chinese medicine, is safe to use and is efficient in treating ischemic heart diseases. The present study aimed to investigate whether Tongguan capsule derived-herb (TGD) can mitigate left ventricular remodeling and dysfunction in post myocardial infarction (MI) rats as well as reduce arrhythmias. Design and methods: MI was induced by a ligation of the left anterior descending coronary artery. TGD was administered to the post-MI rats over a period of 4 weeks. TGD treatment significantly attenuated tachyarrhythmia inducibility and cardiac dysfunction in post-MI heart. Echocardiogram showed that TGD significantly reduced the development of ventricular remodeling. Histological study revealed that TGD significantly reduced myocardial interstitial collagen deposition, myocyte area and alpha-smooth muscle actin (alpha-SMA) expression, and increased connexin 43 expression in the infarcted border zone (IBZ). Western blotting results revealed that TGD treatment significantly down-regulated the protein expression levels of type I and III collagen, alpha-SMA, and upregulated connexin 43. RT-qPCR results showed that TGD decreased the levels of ANP and BNP. Conclusions: These findings provided strong evidences that TGD intervention ameliorated interstitial fibrosis, myocyte hypertrophy and gap junction expression in the IBZ, attenuated left ventricular remodeling and dysfunction, and reduced vulnerability to tachyarrhythmia. TGD inhibited IBZ remodeling by its inhibition effect on myofibroblasts differentiation.
基金:
Natural Science Foundation
of Guangdong Province (No. 2017A030313888, 2016A030313634),TCM Science and Technology Foundation of Guangdong Provincial
Hospital of Chinese Medicine (No. YN2018MJ02, YN2015MS10),
National Natural Science Foundation of China (No. 81503394),
Guangzhou science and Technology Foundation (No. 201607010364),
Guangdong Provincial Key laboratory of Chinese Medicine for
Prevention and Treatment of Refractory Chronic Diseases (No.
2018B030322012).
基金编号:No. 2017A030313888, 2016A030313634
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类|3 区医学
小类|3 区医学:研究与实验3 区药学
最新[2025]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
JCR分区:
出版当年[2017]版:
Q2PHARMACOLOGY & PHARMACYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者机构:[1]The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510006, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Ma Shiyu,Ma Jin,Zhou Yuanshen,et al.Tongguan capsule derived-herb ameliorates remodeling at infarcted border zone and reduces ventricular arrhythmias in rats after myocardial infarction[J].BIOMEDICINE & PHARMACOTHERAPY.2019,120:doi:10.1016/j.biopha.2019.109514.
APA:
Ma, Shiyu,Ma, Jin,Zhou, Yuanshen,Guo, Liheng,Bai, Junqi&Zhang, Minzhou.(2019).Tongguan capsule derived-herb ameliorates remodeling at infarcted border zone and reduces ventricular arrhythmias in rats after myocardial infarction.BIOMEDICINE & PHARMACOTHERAPY,120,
MLA:
Ma, Shiyu,et al."Tongguan capsule derived-herb ameliorates remodeling at infarcted border zone and reduces ventricular arrhythmias in rats after myocardial infarction".BIOMEDICINE & PHARMACOTHERAPY 120.(2019)